Business
Health Logic Interactive Receives Letter of Support from the Director of the Kidney and Blood Pressure Centre at Tufts Medical Center
Health Logic Interactive Receives Letter of Support from the Director of the Kidney and B...
About this update from Health Logic Interactive Inc
[{"type":"text","content":"\n \n \n \n Health Logic Interactive Receives Letter of Support from the Director of the Kidney and Blood Pressure Centre at Tufts Medical Center\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsblb0{\nBORDER-LEFT:black 0pt\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnrbrb0{\nBORDER-RIGHT:black 0pt\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n.prnsbtb0{\nBORDER-TOP:black 0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n CALGARY, AB,\n \n June 29, 2021\n \n /CNW/ -\n \n Health Logic Interactive Inc\n \n . (\"\n \n Health Logic\n \n \" or the \"\n \n Company\n \n \") (TSXV: CHIP.H) (OTCPK: CHYPF), is pleased to announce its wholly-owned operating subsidiary,\n \n My Health Logic\n \n \n Inc.\n \n (\"\n \n My Health Logic\n \n \"), has received a letter of support for the Company's chronic kidney disease (CKD) technology from\n \n Lesley A. Inker\n \n , M.D. MS.  Dr. Inker is the Director of the Kidney and Blood Pressure Center at Tufts Medical Center, an Associate Professor of Medicine at\n \n Tufts University School of Medicine\n \n and a valued member of the Company's scientific advisory board (the \"\n \n SAB\n \n \"). This letter supports the Company's belief that its lab-on-chip device for the early detection of CKD has the potential to address a large and unmet need of patients who have, or are at risk for developing, CKD.\n \n \n \n \n \n \n \n \n \n In her support letter, Dr. Inker, a recent addition to the SAB, stated, \"…this proposed device represents a major innovation in prevention of CKD. Assessment of GFR (glomerular filtration rate) is an essential part of many clinical decisions and having easy access to GFR measurements at home or at the point of care could be transformative. Critically, you are considering the health delivery platform in addition to the technology. The software on a patient's personal devise could allow access to this information at every health encounter an...